|
Carcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
The telomeric one includes the D11S146/BCL1/INT2/HST area and is relevant to DNA amplification in carcinomas and to B-cell translocations.
|
2071147 |
1991 |
|
Carcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas.
|
2098274 |
1990 |
|
Carcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
No coamplification of the hst-1 and int-2 genes was detected in gastric carcinomas and colorectal carcinomas.
|
2529025 |
1989 |
|
Carcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Prognostic significance of hst-1 gene amplification in primary esophageal carcinomas and its relationship to other prognostic factors.
|
8010723 |
1994 |
|
Carcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Concerning band q13: (i) 50 tumors (approximately 17%) were co-amplified for BCL-1, HST & INT-2; (ii) in 3 cases, amplification extended to the SEA gene; (iii) in 6 carcinomas, BCL-1 was the only amplified marker.
|
2181375 |
1990 |
|
Carcinoma of bladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus cyclin D1 and EMS1, but not FGF3 and FGF4, are likely to play a pathogenic role in the 11q13 amplification in bladder cancer.
|
8622895 |
1996 |
|
Carcinoma of bladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
|
14648664 |
2003 |
|
Childhood Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Restriction map of the hst gene from normal leukocyte DNA was identical with that from leukocyte DNA of a leukemia patient, while the hst gene from T361-2nd-1 cells was rearranged at the 168th nucleotide upstream of the TATA box.
|
2895649 |
1988 |
|
Childhood Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our laboratory previously described the independent isolation of the fibroblast growth factor 4 (FGF-4) gene by NIH3T3 transformation assay using DNA from a patient with CML leukemia (Lucas et al., 1994).
|
9050999 |
1997 |
|
Chondrodysplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our novel insights include recognition that the FGF4 retrogene insertion, previously associated with appendicular chondrodysplasia, also reduces neurocranium size.
|
28552356 |
2017 |
|
Choriocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
All cases of embryonal carcinoma (14 cases), yolk sac tumor (3 cases), and choriocarcinoma (3 cases) showed positive immunostaining for FGF8, FGF4, and FGFR1.
|
11764380 |
2001 |
|
Chronic myocardial ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease.
|
18555186 |
2008 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The hst gene was also responsible for acquisition of the transforming activity in DNA samples from 2 other stomach cancers and one colon cancer.
|
3108211 |
1987 |
|
Colorectal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
However, no amplification of the hst-1 gene was detected in gastric and colorectal carcinomas.
|
3136110 |
1988 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results indicate the importance of both silencing the IL-21 gene and co-expression of the FGF4 protein in HCT116 cells, which pave the way for the discovery of important factors to be used as biomarkers for the design of drugs or cost-effective supplements to effectively treat the patients having infectious disease and HCT116 cells of colorectal cancer simultaneously in the future.
|
29802489 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
No coamplification of the hst-1 and int-2 genes was detected in gastric carcinomas and colorectal carcinomas.
|
2529025 |
1989 |
|
Congenital anomaly of cartilage
|
0.010 |
Biomarker
|
group |
BEFREE |
The aim of this study was to determine whether CD- and NCD-derived cartilage differs on a structural and biochemical level, and to explore the relationship between FGF4 associated chondrodystrophy and OA.
|
31373395 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
If these results translated favourably to humans, FGF-4 gene therapy may be a therapeutic option for patients with dilated heart failure.
|
11909005 |
2002 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the porcine Ameroid constrictor model of myocardial ischemia the presence of anti-Ad5 antibodies or prior intracoronary dosing with adenovirus does not prevent the ability of Ad5.FGF4, delivered by intracoronary injection, from normalizing regional myocardial function.
|
16454656 |
2006 |
|
Craniosynostosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
An 11q11-q13.3 duplication, including FGF3 and FGF4 genes, in a patient with syndromic multiple craniosynostoses.
|
17632770 |
2007 |
|
Craniosynostosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Clinical comparison of our patient with those previously reported with overlapping 11q duplications allows us to define the minimal duplicated region associated with craniosynostosis and strongly supports the hypothesis that the constitutional increased dosage of the FGF3 and FGF4 genes is a risk factor for craniosynostosis in humans.
|
24120895 |
2014 |
|
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine whether CD- and NCD-derived cartilage differs on a structural and biochemical level, and to explore the relationship between FGF4 associated chondrodystrophy and OA.
|
31373395 |
2019 |
|
Embryonal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This implicated FGF4 directly in regulating human EC growth or differentiation.
|
9715278 |
1998 |
|
Embryonal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In both EC and ES cell lines, expression of the reporter gene is elevated greatly by the addition of a 316 bp region from the third exon of the murine k-fgf gene.
|
7999355 |
1994 |
|
Endometrial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the levels of FGF-4 mRNA expression were significantly (p < 0.05) lower than those of FGF-1 and -2 mRNAs in both endometrial cancers and normal endometria.
|
8685603 |
1996 |